Pharming Group N.V. (PHARM.AS) Comparison with companies in other sectors?

Pharming Group N.V. has a share price of 685.15M. You can analyze Pharming Group N.V. (PHARM.AS) competitors across different market sectors through stock heatmaps.

What are PHARM.AS's NET and operating margins?

Pharming Group N.V. (PHARM.AS) operating margin is around -0.00, and net profit margin is approximately -0.04 as of the latest reports.

In what way does PHARM.AS's earnings per share (EPS) trend reflect its financial momentum?

Pharming Group N.V. (PHARM.AS) EPS is -0.02 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Pharming Group N.V. is -43.05, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Pharming Group N.V.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Pharming Group N.V. like P/E which is -48.00, P/B which is 3.16, and PEG which is 0.81. Compare them with sector averages to evaluate if the stock is priced fairly.

Pharming Group N.V.

PHARM.AS•EURONEXT

Healthcare

Biotechnology

€0.86

€-0.00(-0.46%)

Fundamental Analysis of Pharming Group N.V. (PHARM.AS)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.02

P/E Ratio

-43.05

ROE

-0.06%

Net Margin

-0.04%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$589.91M

Shares OutstandingTotal number of shares issued

$685.15M

Book Value/ShareNet worth per share

$0.32

Revenue/ShareAnnual revenue per share

$0.48

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.02

Net MarginNet income as percentage of revenue

-4.39%

Operating MarginOperating income as percentage of revenue

-0.07%

ROEReturn on shareholders' equity

-6.47%

ROAReturn on total assets

-3.50%

ROCEReturn on capital employed

-0.07%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.008

Cash/ShareCash and equivalents per share

$0.16

FCF YieldFree cash flow as percentage of market cap

0.74%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for PHARM.ASFinancial Ratios Analysis details for PHARM.AS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for PHARM.ASSector Benchmarking details for PHARM.AS are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Pharming Group N.V. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Pharming Group N.V.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Pharming Group N.V.'s unique business strengths and challenges.

Key Financial Metrics for Pharming Group N.V.

For Pharming Group N.V., essential financial indicators include EPS -0.02, PE -43.05, and ROE -0.06. These key ratios reveal insights into Pharming Group N.V.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Pharming Group N.V. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Pharming Group N.V.

Metrics like Net Margin -4.39% and ROA -3.50% shed light on how well Pharming Group N.V. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Pharming Group N.V. can sustain its operations and continue growing in the future.

Valuation and Market Position of Pharming Group N.V.

Using ratios such as P/B Ratio 3.16 and PEG Ratio 0.81, investors can assess whether Pharming Group N.V. is appropriately valued based on its financials and growth potential. These figures, combined with Pharming Group N.V.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Pharming Group N.V.

Financial health indicators, such as Debt/Equity Ratio 0.56 and Cash Flow $0.008, provide a snapshot of Pharming Group N.V.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Pharming Group N.V., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Pharming Group N.V.

Investing in Pharming Group N.V. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Pharming Group N.V. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;